Pylarify (piflufolastat f 18)
Ended Awarded Last action
- Contract number
- 36C26224F0426
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 22
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $676,004
Award facts
- Contract value 20% obligated
-
- $676,004.48 Current, with exercised options
- $3,320,022.40 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Loma Linda, CA 92357, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $676,004 |
About this award
On September 23, 2024, Veterans Integrated Service Network 22 (a component of the Department of Veterans Affairs) awarded a delivery order valued at $3.32 million to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc., for the supply of PYLARIFY (piflufolastat F-18), a radioactive diagnostic imaging agent used in positron emission tomography (PET) scans for prostate cancer detection. This firm fixed-price contract, with performance concluding August 31, 2025, is not set aside and will be performed at the awardee's facility in Loma Linda, California. The delivery order is issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), which enables federal healthcare providers to efficiently procure critical radiopharmaceutical products.
This award represents a task order against Progenics Pharmaceuticals' broader federal supply schedule contract vehicle, which supports the VA's diagnostic imaging programs across its medical centers nationwide. Progenics Pharmaceuticals, operating under parent company Lantheus Holdings, Inc., has consistently supplied PYLARIFY and other specialized nuclear medicine products to federal healthcare agencies. The contract supports the VA's commitment to providing advanced diagnostic capabilities for cancer detection and treatment planning, leveraging the company's expertise in radiopharmaceutical development and distribution to military treatment facilities and VA medical centers.
Quick answers
Who was awarded contract 36C26224F0426?
36C26224F0426 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 22 (Veterans Health Administration) on September 23, 2024.
How much is contract 36C26224F0426 worth?
The government has obligated $676,004 on 36C26224F0426. Its potential value, with all options, is $3,320,022.
Is contract 36C26224F0426 an order under another contract?
Yes. 36C26224F0426 is a delivery order under 36F79719D0170, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26224F0426 competed?
The extent of competition for 36C26224F0426 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award